65,437 trials
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
Surgical Conditions
Primary: Leiden Surgical Rating Scale — 4.8; 4.8 score on a scale — p=0.94
Essential Tremor of the Upper Limbs
Primary: Change From Baseline to Week 4 in Maximum Angular Tremor Amplitude of the Wrist (Injected Limb) — -0.47; 0.07 degree — p=0.144
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Adverse Events — 11; 7 participants
Replacement Therapy, Renal
Primary: Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC) — 0; 0; 19; 16 Participants
Aphasia
Primary: Naming Reaction Time — 1829.11; 3345.97 milliseconds
Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 4 — 43.7; 43.5 percentage of participants — p=0.939
Lupus Erythematosus, Systemic
Primary: Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response — 29; 20; 33; 44 Number of participants — p=0.214
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Smoking Cessation
Primary: Feasibility - Helpfulness and Ease of Use of the Intervention Smartphone App — 2; 2; 1; 0 Participants
Hip Fractures
Primary: Success Rate (Supplemental Medication) — 22; 20; 3 Participants
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Idiopathic Parkinson Disease
Primary: Change From Baseline in Movement Disorders Society -Unified Parkinson's Disease Rating Scale (MDS-UPDRS) — -5.0; -1.0; -1.9; 0.0 score on a scale
HIV Infections
Primary: Occurrence of Vaccine-induced Systemic IgG Ab Binding to the 3 gp120 Env Proteins Contained in the Vaccine Regimen (ZM96, TV1.C, and 1086.C) in Group 1 and Group 2 — 29…
Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLT): Phase 1b — 0 Participants